Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||alphaDC1 + NK-like CTLs|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NK-like CTLs||autologous NK-like CTLs|autologous aDC1-induced CTLs||NK-like CTLs (nCTLs) are autologous T-lymphocytes that are treated with autologous alpha-type-1 dendritic cells that have been exposed to patient-specific tumor antigens, which potentially results in natural killer-like activity and increased tumor cell lysis (NCI Drug Dictionary).|
|alphaDC1||alpha-type-1-polarized DC|Alpha-type-1 Polarized Dendritic Cells||alphaDC1 is a polarized DC1 vaccine comprising autologous dendritic cells that is matured by treating with chemokines, potentially resulting in enhanced cytokine production and anti-tumor immune response against tumor cells (PMID: 15342370).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03735589||Phase Ib/II||alphaDC1 + NK-like CTLs||Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Not yet recruiting||USA||0|